BoironLTS:0DTF 73 Net Margin % is 8.33% as of Dec. 2025, which is 14% above its 10-year median of 7.28. GuruFocus rates LTS:0DTF with a GF Score™ of 73/100 and a GF Value™ of €33.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Boiron ranks better than 53.66% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Boiron's Net Income for the
six
months ended in Dec. 2025 was €21.3 Mil. Boiron's Revenue for the
six
months ended in Dec. 2025 was €255.5 Mil. Therefore, Boiron's net margin for the quarter that ended in Dec. 2025 was 8.33%.
The historical rank and industry rank for Boiron's Net Margin % or its related term are showing as below:
LTS:0DTF'
s Net Margin % Range Over the Past 10 Years
Min: 2.33 Med: 7.28 Max: 12.67
Current: 6.51
LTS:0DTF's Net Margin % is ranked better than 53.66% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs LTS:0DTF: 6.51
Boiron (LTS:0DTF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Boiron Net Margin % Related Terms
Boiron Net Margin % Historical Data
* Premium members only.
The historical data trend for Boiron's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DTF vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's Net Margin % distribution charts can be found below:
* The bar in red indicates where Boiron's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (LTS:0DTF) has a Net Margin % of 8.33% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Boiron and its competitors. This is 14% above median its historical median of 7.28. Over the past decade, Boiron's Net Margin % has ranged from 2.33 to 12.67. According to the industry distribution chart, Boiron ranks #443 out of 956 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Boiron's Net Margin % too high?
Boiron's current Net Margin % of 8.33% is 14% above median its 10-year median of 7.28. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 12.67. The Drug Manufacturers industry median Net Margin % is 5.56. Boiron's value of 8.33% is 49.8% above this industry median. Based on the distribution chart, Boiron ranks #443 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Boiron has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boiron's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #443 out of 956 companies for Net Margin %. This puts Boiron in the upper half of its industry. The industry median Net Margin % is 5.56. Boiron's value of 8.33% is 49.8% above this benchmark. Historically, Boiron's own Net Margin % has ranged from 2.33 to 12.67 over the past decade. While the company's 10-year median is 7.28 vs. the industry median of 5.56, Boiron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current Net Margin % of 8.33% is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current Net Margin % is 8.33%, which is 14% above median its own 10-year median of 7.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (LTS:0DTF) is currently considered Modestly Undervalued. The stock's GF Value™ is €33.63, compared to a current price of €27.70 — trading 17.6% below its estimated fair value. The current Net Margin % is 8.33%, which is 14% above median its 10-year median of 7.28 and 49.8% above the Drug Manufacturers industry median of 5.56. Boiron's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Boiron (LTS:0DTF), the current Net Margin % is 8.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (LTS:0DTF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of €27.70 is trading 17.6% below its estimated GF Value™ of €33.63.
GuruFocus considers Boiron to be Modestly Undervalued.
Key valuation signals for LTS:0DTF:
Net Margin %: 8.33% (14% above median its 10-year median of 7.28)
GF Value™: €33.63 vs. price of €27.70 (17.6% below fair value)
Industry Position: 49.8% above the Drug Manufacturers median (#443 of 956)
No single metric tells the full story. See the LTS:0DTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
73GF Score
Get the complete analysis for LTS:0DTF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DTF has been successfully added to your 
